Celastrol alleviates esophageal stricture in rats by inhibiting NLR family pyrin domain containing 3 activation

Figure 7 The effect of celastrol on NLR family pyrin domain containing 3 activation in vivo. Data presented as mean ± SE. Statistical analysis was performed using Dunnett’s multiple comparison test, with the “vehicle” group as the control. A: Western blot analysis of NLR family pyrin domain containing 3 (NLRP3) and interleukin (IL)-1β in the esophageal ulceration area of rat tissues on day 6. ^aP < 0.001; ^bP < 0.001; ^cP = 0.004; ^dP = 0.01; ^eP < 0.001; ^fP = 0.01; B: mRNA levels of NLRP3 and IL-1β in rat esophagus on day 6. ^gP = 0.009; ^hP = 0.001; ⁱP = 0.01; ^jP = 0.02; ^kP < 0.001; ^LP < 0.001; ^mP = 0.002; ⁿP = 0.009; C: Representative immunohistochemistry (IHC) image of NLRP3 in the esophageal ulceration area of rats. Scale bar = 80 μm, 20 μm; D: Quantitative analysis of the NLRP3-positive area (%) for IHC, ^oP = 0.004; ^pP = 0.02; ^qP = 0.01; NLRP3: NLR family pyrin domain containing 3; CEL: Celastrol; PRED: Prednisolone; LPS: Lipopolysaccharide.